You know, it’s true -- there’s no place like home (especially Antibody Solutions’ new home in Santa Clara, California). At the same time, though, I probably would have stayed another week in Boston had there been a third conference that was as chock full of engaging presentations, intriguing research and useful data (plus some very stimulating hallway conversations) as the two back-to-back conferences I attended earlier this month: CAR-TCR Summit 2019 and Discovery on Target 2019.
Chimeric antigen receptor (CAR-T) cell therapy
A growing number of CAR-T cell therapies are being developed and tested in clinical studies as an innovative approach to reprogram the patient’s immune system to attack its own abnormal cells. For treatment of certain cancers, as well as other diseases, this is a huge leap forward.
Editor’s Note: This is the third and final post in a series on Dr. Oren Beske of ATUM and his climb up Mt. Kilimanjaro in support of the Fred Hutchinson Cancer Research Center. In an effort to avoid spoiling his inspiring last installment, we’ll just invite you to catch up on Oren’s first and second posts and then jump right in below.
Our thanks and congratulations to Oren and to all of you for supporting this terrific initiative!
Co-Founder and CEO, Antibody Solutions
Editor’s Note: Here’s the second installment in a blog post series we’re excited to present in conjunction with our friend and colleague Dr. Oren Beske of ATUM. If you missed Oren’s first post on his climb to help the Fred Hutchinson Cancer Research Center, you can read it here.
Thanks for continuing this journey with us. Onward and, more importantly, upward!
Co-Founder and CEO, Antibody Solutions
Post-Show Perspectives: Next-Generation CAR and T Cell Therapies
June 18-20, 2019 | Park Central Hotel, San Francisco, Calif.
A few weeks ago, a group of us from Antibody Solutions headed up the highway from Sunnyvale (our old home) to San Francisco where we attended the “Next-Generation CAR and T Cell Therapies” conference. In short, the event was well worth the investment of time, and we look forward to participating in similar conferences in the future.
Editor’s Note: We’re proud to present our first in a series of reflections from our friend and colleague, Dr. Oren Beske of ATUM. We think you’ll find the journey he’s on—one that’s both acutely personal yet wholly universal—to be inspiring and thought-provoking. At Antibody Solutions, we share the end goal of our oncology drug development partners and clients: To extend the quality and quantity of life for cancer patients, and, once and for all, to pitch cancer headfirst into the dustbin of medical history. We salute Oren and all those supporting the Fred Hutchinson Cancer Research Center (or, in shorthand, “Fred Hutch”). Climb well!
Agreement Provides for Easy Access to the Transgenic H2L2 Harbour Mice™ Platform with Antibody Solutions’ Discovery and Development Services
When you think about the rat IgG production and purification process (especially IgG2a), what words often come to mind? If you’re like most researchers, it’s probably a combination of these: frustration, missed timelines, low purity, and poor recovery.
What do you get when you inject 2,600 participants into more than 400 sessions, 300-plus research posters and more than 150 exhibitors and then put ‘em all next to Boston Harbor for a week?
PepTalk 2019: The Protein Science Week
January 14-18, 2019 | San Diego Hilton Bayfront, San Diego, Calif.
Earlier this month, I had the good fortune to attend the “Keystone Joint Symposia” event in Keystone, Colo. (and yes, it was much colder than at Antibody Solutions’ headquarters in Sunnyvale, Calif.!).The speakers during the sessions had two primary goals: (1) to present the most recent advances in the biology of T cell-dependent B cell responses; and (2) to explore how our understanding of B-T cell interactions influence antibody generation and inform vaccine development.
We are occasionally asked about the success rate of different antibody platforms for drug discovery. There are a variety of technologies available for therapeutic antibody discovery: conventional mice where the Abs are humanized, human Ab transgenic rodents, human Ab synthetic phage and yeast libraries, and others.
Antibody Solutions will be attending Keystone Symposia's Molecular Approaches 2019, to be held February 10-15 in Keystone, CO.
Antibody Solutions will be attending PEGS 2019, to be held April 8-12 in Boston, MA.
Antibody Solutions will be attending Next Generation CAR & T Cell Therapies 2019, to be held June 18-20 in San Francisco, CA.
Antibody Solutions will be attending CAR-TCR Summit 2019, to be held September 10-13 in Boston, MA.
Antibody Solutions will be attending Discovery On Target 2019, to be held September 17-19 in Boston, MA.
Antibody Solutions will be attending PEGS Europe 2019, to be held November 18-22 in Lisbon, Portugal.
Antibody Solutions will be attending Antibody Engineering & Therapeutics 2019, to be held December 9-13 in San Diego, CA.
Antibody Solutions will be attending PepTalk 2019, to be held January 14-18 in San Diego, CA.
Antibody Solutions, a leader in discovery of therapeutic, biomarker and critical reagent antibodies, and Single Cell Technology, Inc. (SCT), a pioneer in single cell analysis technology, have launched a partnership that offers pharmaceutical researchers one-stop access to advanced single B-cell antibody discovery capabilities.